Media about us

  • 17 May 2017

    Syndax shares soar as lead drug clears a mid-stage cancer drug study hurdle

    John Carroll / Endpoints News

    Briggs Morrison has good reason today to be glad he left the Big Pharma R&D world behind at AstraZeneca and switched to biotech. The CEO of Waltham, MA-based Syndax reported that the company’s lead drug in combination with Merck’s Keytruda cleared its first big hurdle in Phase II and will now transition into the second phase of the study.

  • 02 May 2017

    Epic Sciences nets $40M for cancer liquid biopsy

    Epic Sciences nets $40M for cancer liquid biopsy

    Amirah Al Idrus / FierceBiotech

    Epic Sciences raised $40 million in a Series D round, which it will use to ramp up clinical studies of its liquid biopsy tests that identify cancer patients who will benefit from specific treatments.

  • 02 May 2017

    Biopharma just can’t get enough of Epic Sciences

    Biopharma just can’t get enough of Epic Sciences

    Juliet Preston / MedCityNews

    Epic Sciences has to be one of the coolest kids on the biopharma block, with a new $40 million Series D financing round, a whopping 42 industry partnerships and over 200 clinical trials in the works, all built around its novel liquid biopsy platform. For a team of just 70, the San Diego, California startup is doing pretty well.

  • 02 May 2017

    With $40M in New Cash, Epic Sciences Advances Diagnostic for Late-Stage Prostate Cancer

    With $40M in New Cash, Epic Sciences Advances Diagnostic for Late-Stage Prostate Cancer

    Bruce V. Bigelow / Xconomy

    When San Diego’s Epic Sciences raised $30 million almost three years ago, CEO Murali Prahalad told me he saw a big opportunity to use the company’s technology as a diagnostic test to assess how well a cancer patient is responding to specific anti-cancer drug regimens.

  • 10 April 2017

    Corneal inlays need your boost to hit their stride

    Corneal inlays need your boost to hit their stride

    John A. Hovanesian, MD, FACS / Healio

    Recently, ReVision Optics announced the implantation of the 1,000th Raindrop corneal inlay in the United States since its approval last August. The AcuFocus Kamra corneal inlay, which was approved earlier, has now reached nearly 4,000 U.S. implants, according to a source at the company.

  • 07 March 2017

    New help for that bane of middle-age: blurry close-up vision

    New help for that bane of middle-age: blurry close-up vision

    Lauran Neergaad, AP Medical Writer / Associated Press

    Squinting while texting? Always losing your reading glasses? An eye implant that takes about 10 minutes to put in place is the newest in a list of surgical repairs for the blurry close-up vision that is a bane of middle age. But who's really a good candidate to toss their specs?

  • 16 February 2017

    Atlas to invest in extra capacity at STI test manufacturing partner Bespak

    Atlas to invest in extra capacity at STI test manufacturing partner Bespak

    Dani Bancroft / InPharma Technologist.com

    Atlas Genetics has said it will expand manufacturing capacity for cartridgebased STI tests at a UK facility owned by drug delivery technology firm Bespak Europe ltd.

  • 15 February 2017

    Liquid biopsies: The next frontier in cancer?

    Liquid biopsies: The next frontier in cancer?

    Ned Pagliarulo / BioPharmaDive

    As immuno-oncology dazzles and pharma companies race to develop new cancer medicines, a similar boom is underway to speed up and improve the detection of cancers.

  • 01 February 2017

    Top 5 Vendors in the Pharmerging Market from 2017 to 2021: Technavio

    Top 5 Vendors in the Pharmerging Market from 2017 to 2021: Technavio

    Yahoo Finance

    The pharmaceutical industry worldwide witnesses a dramatic regional shift to the pharmerging market, owing to the opportunities available. Considering the on-going trend of shift in global medicine dosage consumption to developing countries, about 55-60% of the global consumption should come from pharmerging markets by 2021. This will eventually lead to an incremental growth of around 25% from 2016 level.

  • 24 January 2017

    Struggling Marinus gets a bump out of a positive PhII snapshot

    Struggling Marinus gets a bump out of a positive PhII snapshot

    Arsalan Arif / Endpoints News

    A lit­tle more than six months since its stock price was crushed by a failed late-stage pro­gram for its lead­ing — and only — drug, tiny biotech mi­cro­cap Mar­i­nus $MRNS saw its shares shoot up this morn­ing after it of­fered a pos­i­tive Phase II snap­shot on a hand­ful of pa­tients who suf­fer from a rare ge­netic ail­ment.

All Partners

All Portfolio

MEDIA CENTER

  • NovaMedica launched Technology Center to develop innovative drugs

    NovaMedica launched Technology Center to develop innovative drugs

    NovaMedica, a Russian pharmaceutical company (RUSNANO portfolio company), started operation of the Technology Center designed for the development and pilot production of innovative drug products. It comprises a complex of R&D laboratories and production areas with technological capabilities which are unique for the Russian pharmaceutical industry and one of the best in Europe. Crucial tasks of the Technology Center are to develop the advanced oral medical products of different pharmacotherapeutic groups, including those to treat cardiovascular and gastroenterological diseases, central nervous system diseases, and to create painkillers drugs of the new generation.  

All news